TYRA Stock — Tyra Biosciences Inc.: Cash, EV, Pipeline

What they do

We are a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. Our in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help us design and predict which product candidates may demonstrate the highest potency, selectivity and tolerability in the clinic.

Source: 10-K FY2025 via SEC EDGAR

Share price

$21.15

Market cap

$1,454.2M

Cash

$727.8M

Enterprise value

$726.4M

Balance sheet

Cash	$727.8M
Debt	$0.0M
Net cash	$727.8M
Enterprise value	$726.4M
Basic shares	59.7M shares
Fully diluted shares	81.6M shares
Fully diluted market cap	$1,726.4M
Cash per share	$12.20
Quarterly burn	$31.1M
Cash runway	23.4 quarters

Cash figures as of 2026-09-15. Database snapshot: 2026-11-07.

Share structure

Common

59.7M

Pre-funded warrants

6.4M

Options

13.6M

RSUs

—

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

2.0M

FDSO

81.6M

Cap table as of 2026-07-31.

Price history

Loading TYRA daily closes…

Loading price history…

Next catalyst

TYRA-300 · Dec 13, 2026 - Jan 24, 2027 in 5 wks · Phase 2 · Locally Advanced Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Solid Tumor

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Dec 13, 2026 - Jan 24, 2027 in 5 wks	TYRA-300	Phase 2	Locally Advanced Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Solid Tumor	—
GUIDEDEst. Feb 14, 2027 in 8 wks quarter midpoint	TYRA-300 (dabogratinib) BEACH301 Phase 2 safety-sentinel cohort in pediatric skeletal dysplasias	Phase 2	pediatric skeletal dysplasias	end of Q1 2027
Feb 12 - Mar 25 in 15 mo	TYRA-430	Phase 1	Metastatic Hepatocellular Carcinoma; Solid Tumors; Solid Tumor, Adult	—
Mar 14 - Apr 25 in 16 mo	TYRA-300 60mg	Phase 2	Low-grade NMIBC; FGFR Gene Amplification; FGFR Gene Alterations	—
Nov 12 - Dec 24 in 49 mo	Dabogratinib (TYRA-300) 60mg	Phase 2	Low Grade Upper Tract Urothelial Carcinoma	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

dabogratinib

Phase 2 · Active Modality: small molecule (oral; FGFR3-selective)

Target FGFR3

Indications

Low-grade upper tract urothelial carcinoma (LG-UTUC) (Phase 2)
Intermediate-risk non-muscle invasive bladder cancer (IR NMIBC) (Phase 2)
Achondroplasia (children) (Phase 2)

Catalysts

— Sep 2026
— Q1 2027
— 2027

Status note 'Dabogratinib 3x3' strategy: three Phase 2 trials (SURF303, SURF302, BEACH301) toward three potential registrational trials.

TYRA-430

Phase 1 · Active Modality: small molecule (oral; FGFR4/FGFR3-biased)

Target FGFR4 / FGFR3

Indications

FGF19-positive hepatocellular carcinoma (Phase 1)

Status note SURF431 global Phase 1 open-label trial focused on clinical proof-of-concept in FGF19+ HCC.

TYRA-200

Phase 1 · Active Modality: small molecule (oral; FGFR1/2/3 inhibitor)

Target FGFR1 / FGFR2 / FGFR3

Indications

FGFR2-driven intrahepatic cholangiocarcinoma resistant to prior FGFR inhibitors (Phase 1)

Status note SURF201 global Phase 1 open-label trial; designed active against acquired pan-FGFR inhibitor resistance mutations.

Per-asset detail extracted from the 10-Q filed 2026-08-04. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	TYRA-300
Lead indication	Locally Advanced Urothelial Carcinoma
Lead phase	Phase 2
Active trials	7

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05544552	Phase 2	Active, not recruiting	Sponsor	TYRA	—	Locally Advanced Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Solid Tumor	—
NCT06995677	Phase 2	Recruiting	Sponsor	TYRA	—	Low-grade NMIBC; FGFR Gene Amplification; FGFR Gene Alterations	—
NCT06842355	Phase 2	Recruiting	Sponsor	TYRA	—	Achondroplasia	—
NCT07265947	Phase 2	Recruiting	Sponsor	TYRA	—	Low Grade Upper Tract Urothelial Carcinoma	—
NCT06915753	Phase 1	Recruiting	Sponsor	TYRA	—	Metastatic Hepatocellular Carcinoma; Solid Tumors; Solid Tumor, Adult	—
NCT06006702	Phase 1	Active, not recruiting	Sponsor	TYRA	—	Healthy	—
NCT06160752	Phase 1	Active, not recruiting	Sponsor	TYRA	—	Locally Advanced Cholangiocarcinoma; Intrahepatic Cholangiocarcinoma; Solid Tumor	—

Sponsor-matched active trials from ClinicalTrials.gov (7 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 7 active trials for Tyra Biosciences, Inc on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
RA Capital Management	12,198,625	no change	3.39%	2026-08-14
BVF Partners	1,476,196	-500,000	1.21%	2026-08-14
Deerfield Management	1,017,000	+468,000	0.34%	2026-08-14
OrbiMed Advisors	102,000	+102,000	0.06%	2026-08-14
Baker Bros. Advisors	10,607	no change	0.00%	2026-08-14
Logos Global Management	0	-850,000	0.00%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

TYRA — Tyra Biosciences Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

TYRA — Tyra Biosciences Inc.